Search results for " pancreatic"

showing 10 items of 149 documents

Late postpancreatectomy hemorrhage after pancreaticoduodenectomy: is it possible to recognize risk factors ?

2012

Context Post-pancreatectomy hemorrhage is one of the most common complications after pancreaticoduodenectomy. Objective To evaluate the late post-pancreatectomy hemorrhage rate according to the International Study Group of Pancreatic Surgery criteria and to recognize factors related to its onset. Methods A prospective study of 113 patients who underwent pancreaticoduodenectomy was conducted. Late post-pancreatectomy hemorrhage was defined according to the criteria of the International Study Group of Pancreatic Surgery. Demographic, clinical, surgical and pathological data were considered and related to late post-pancreatectomy hemorrhage. Results Thirty-one (27.4%) patients had a post-pancr…

MaleTime FactorsIncidencePancreatectomy Hemorrhage Pancreatic FistulaHemorrhageComorbidityMiddle AgedCarcinoma NeuroendocrinePancreatic NeoplasmsAdenocarcinoma PapillaryPancreatic FistulaSettore MED/18 - Chirurgia GeneralePancreatectomyPostoperative ComplicationsRisk FactorsPancreatitis ChronicHumansFemaleProspective StudiespancreaticoduodenectomyAgedCarcinoma Pancreatic Ductal
researchProduct

Germline copy number variation in theYTHDC2gene: does it have a role in finding a novel potential molecular target involved in pancreatic adenocarcin…

2014

Abstract: Objective: The vast majority of pancreatic cancers occurs sporadically. The discovery of frequent variations in germline gene copy number can significantly influence the expression levels of genes that predispose to pancreatic adenocarcinoma. We prospectively investigated whether patients with sporadic pancreatic adenocarcinoma share specific gene copy number variations (CNVs) in their germline DNA. Patients and methods: DNA samples were analyzed from peripheral leukocytes from 72 patients with a diagnosis of sporadic pancreatic adenocarcinoma and from 60 controls using Affymetrix 500K array set. Multiplex ligation-dependent probe amplification (MLPA) assay was performed using a s…

Malecopy number variations germline alteration pancreatic cancer susceptibility YTHDC2 geneDNA Copy Number VariationsSettore MED/06 - Oncologia MedicaClinical BiochemistryAdenocarcinomaBiologyGermlinePancreatic cancerDrug DiscoverymedicineHumansGenetic Predisposition to DiseaseMultiplexProspective StudiesMultiplex ligation-dependent probe amplificationCopy-number variationAlleleGeneGerm-Line MutationAgedAdenosine TriphosphatasesAged 80 and overPharmacologyPharmacology. TherapyDNA HelicasesMiddle Agedmedicine.diseaseMolecular biologyPancreatic NeoplasmsCase-Control StudiesMolecular MedicineAdenocarcinomaFemaleMultiplex Polymerase Chain ReactionRNA HelicasesExpert Opinion on Therapeutic Targets
researchProduct

Micro-RNA in pancreatic adenocarcinoma: Predictive/prognostic biomarkers or therapeutic targets?

2015

Pancreatic ductal adenocarcinoma (PDAC) is a tumor with a poor prognosis, short overall survival and few chemotherapeutic choices. MicroRNAs (miRNAs) are non-coding, single-stranded RNAs of around 22 nucleotides involved in the pathogenic mechanisms of carcinogenesis and metastasis. They have been studied in many tumors in order to identify potential diagnostic, prognostic or therapeutic targets. In the current literature, many studies have analyzed the role of miRNAs in PDAC. In fact, the absence of appropriate biomarkers, the difficultly of early detection of this tumor, and the lack of effective chemotherapy in patients with unresectable disease have focused attention on miRNAs as new, i…

Maleendocrine system diseasesPrognosiSettore MED/06 - Oncologia MedicaMice NudeReviewDiseaseAdenocarcinomaMalignancymedicine.disease_causeMetastasisMicemicroRNABiomarkers TumorCarcinomamedicineAnimalsHumansmiRNAbiomarkers; miRNAs; pancreatic adenocarcinoma; prognosis; therapyAnimalbusiness.industryPancreatic NeoplasmbiomarkersMicroRNABiomarkerPrognosismedicine.diseasePhenotypedigestive system diseasesPancreatic NeoplasmsGene Expression Regulation NeoplasticMicroRNAsPhenotypeBiomarkers; miRNAs; Pancreatic adenocarcinoma; Prognosis; Therapy; Adenocarcinoma; Animals; Biomarkers Tumor; Carcinoma Pancreatic Ductal; Female; Gene Expression Regulation Neoplastic; Humans; Male; Mice; Mice Nude; MicroRNAs; Pancreatic Neoplasms; Phenotype; Prognosis; OncologyOncologymiRNAsImmunologyCancer researchAdenocarcinomaFemaleTherapybusinessCarcinogenesisPancreatic adenocarcinomaCarcinoma Pancreatic DuctalHuman
researchProduct

Exocrine pancreatic function in children with coeliac disease before and after a gluten free diet.

1991

This study was designed to determine the extent of pancreatic insufficiency in untreated coeliac disease and whether pancreatic secretion is impaired after a prolonged gluten free period. Three groups of patients were studied: group A comprised 44 patients, mean (SD) age 4.0 (3.1) years, with coeliac disease and total or subtotal atrophy of the intestinal mucosa; group B comprised 67 patients, mean age 4.4 (3.0) years, with coeliac disease but with normal morphology of the intestinal villi (after 12.9 months of a gluten free diet); group C comprised 49 control subjects, mean age 3.2 (3.0) years, with normal jejunal histology. In all subjects exocrine pancreatic function was determined by th…

Malemedicine.medical_specialtyAdolescentGlutensDuodenumDiet therapyGastroenterologyCoeliac diseaseSecretinFecesSecretinIntestinal mucosaInternal medicinemedicineChymotrypsinHumansIntestinal MucosaChildExocrine pancreatic insufficiencyPancreasbusiness.industryGastroenterologyInfantmedicine.diseasedigestive system diseasesCeliac DiseaseEndocrinologymedicine.anatomical_structureChild PreschoolDuodenumExocrine Pancreatic InsufficiencyFemaleGluten freePancreasbusinessCeruletideResearch ArticleGut
researchProduct

Effects of experimental type 1 diabetes and exercise training on angiogenic gene expression and capillarization in skeletal muscle.

2006

Diabetes alters microvascular structure and function and is a major risk factor for cardiovascular diseases. In diabetic skeletal muscle, impaired angiogenesis and reduced VEGF-A expression have been observed, whereas in healthy muscle exercise is known to have opposite effects. We studied the effects of type 1 diabetes and combined exercise training on angiogenic mRNA expression and capillarization in mouse skeletal muscle. Microarray and real-time PCR analyses showed that diabetes altered the expression of several genes involved in angiogenesis. For example, levels of proangiogenic VEGF-A, VEGF-B, neuropilin-1, VEGFR-1, and VEGFR-2 were reduced and the levels of antiangiogenic thrombospon…

Malemedicine.medical_specialtyAngiogenesisNeovascularization PhysiologicMice Inbred StrainsBiologyBiochemistryDiabetes Mellitus ExperimentalNeovascularizationMiceInternal medicineDiabetes mellitusPhysical Conditioning AnimalGene expressionGeneticsmedicineAnimalsMuscle SkeletalMolecular BiologyRegulation of gene expressionType 1 diabetesNeovascularization PathologicSkeletal muscleRibonuclease Pancreaticmedicine.diseaseCapillariesDisease Models Animalmedicine.anatomical_structureEndocrinologyDiabetes Mellitus Type 1Gene Expression RegulationAngiogenesis Inducing Agentsmedicine.symptomAngiogenesis Inducing AgentsBiotechnologyFASEB journal : official publication of the Federation of American Societies for Experimental Biology
researchProduct

Epidemiology of pancreatic neuroendocrine neoplasms. a gender perspective

2020

Purpose: Pancreatic neuroendocrine neoplasms (PNENs) are a group of clinically rare and heterogeneous tumors of the pancreas. Currently there are no studies investigating the gender difference in PNEN susceptibility. Thus, the purpose of this study was aimed at examining how gender shapes risk factors, clinicopathological features, and comorbidities in PNENs. Methods: The study design consisted of an Italian multicenter, retrospective study. The study included all consecutive patients with PNENs followed at the participating centers. Two hundred and twenty-nine patients (105 males,124 females, age 54 ± 0.98 years) with PNENs were enrolled at the participating centers. The clinicopathologica…

Malemedicine.medical_specialtyCardiovascular diseases; Epidemiology; Gender; Pancreatic neuroendocrine neoplasms; Sex; Type 2 diabetes; Female; Humans; Male; Middle Aged; Pancreas; Retrospective Studies; Diabetes Mellitus Type 2; Neuroendocrine Tumors; Pancreatic NeoplasmsPancreatic neuroendocrine neoplasmEndocrinology Diabetes and Metabolism030209 endocrinology & metabolismType 2 diabetesDiseaseNeuroendocrine tumorsType 2 diabete03 medical and health sciences0302 clinical medicineEndocrinologyRetrospective StudieInternal medicineDiabetes mellitusEpidemiologymedicinegenderPancreaHumanssexPancreasRetrospective Studiesbusiness.industrypancreatic neuroendocrine neoplasmsRetrospective cohort studyMiddle Agedmedicine.diseaseCardiovascular diseasecardiovascular diseasesNatural historyPancreatic NeoplasmsNeuroendocrine TumorsDiabetes Mellitus Type 2030220 oncology & carcinogenesisPancreatitisFemaleepidemiologytype 2 diabetescardiovascular diseases; epidemiology; gender; pancreatic neuroendocrine neoplasms; sex; type 2 diabetesbusinessNeuroendocrine TumorHuman
researchProduct

Modified FOLFIRINOX versus CisGem first-line chemotherapy for locally advanced non resectable or metastatic biliary tract cancer (AMEBICA)-PRODIGE 38…

2019

IF 3.287 (2017); International audience; IntroductionCombination of cisplatine and Gemcitabine (CisGem) is the reference 1st line Chemotherapy in patients with advanced biliary cancer. FOLFIRINOX demonstrated an overall survival superiority when compared to gemcitabine in 1st line for patients with metastatic pancreatic adenocarcinoma. Because of similarities between pancreatic and biliary cancers, we proposed a randomized trial comparing mFOLFIRINOX and CisGEm.AimPRODIGE38-AMEBICA is a phase II/III trial evaluating efficacy of modifed FOLFIRINOX (D1 bolus removed) or CisGEm on patients with locally advanced non resectable or metastatic biliary tract cancer.Patients and methodsMain inclusio…

Malemedicine.medical_specialtyFOLFIRINOXmedicine.medical_treatmentModified folfirinoxLeucovorinAntineoplastic Agents[SDV.CAN]Life Sciences [q-bio]/CancerAdvanced biliary cancerIrinotecanDeoxycytidineGastroenterology03 medical and health sciences0302 clinical medicineInternal medicineAntineoplastic Combined Chemotherapy ProtocolsCarcinomaHumansMedicineNeoplasm InvasivenessNeoplasm StagingChemotherapyHepatologybusiness.industryGallbladderCarcinomaGastroenterologyMetastatic Pancreatic Adenocarcinomamedicine.diseaseGemcitabinePrimary tumorGemcitabine3. Good healthOxaliplatinmedicine.anatomical_structureBile Duct NeoplasmsBiliary tract030220 oncology & carcinogenesisFemale030211 gastroenterology & hepatologyFluorouracilFranceCisplatinDrug Monitoringbusinessmedicine.drug
researchProduct

Use of famotidine in severe exocrine pancreatic insufficiency with persistent maldigestion on enzymatic replacement therapy. A long-term study in cys…

1992

In patients with pancreatic exocrine insufficiency, the use of pancreatic enzyme does not abolish steatorrhea in some cases. We carried out a long-term prospective study in an attempt to clarify the effectiveness of the associated use of famotidine to enzymatic supplementation on fat absorption and nutritional parameters of patients with pancreatic insufficiency due to cystic fibrosis. We studied 10 patients, mean age 12.5 years, with persistent steatorrhea on enzymatic supplementation. A double-blind crossover design was used and famotidine (1 mg/kg/day) or placebo was given as adjuvant to enzymatic preparations for either of two six-month periods. A statistically significative reduction i…

Malemedicine.medical_specialtyPancreatic diseaseAdolescentCystic FibrosisPhysiologyGrowthPlaceboCystic fibrosisGastroenterologyInternal medicinemedicineHumansProspective StudiesAdverse effectExocrine pancreatic insufficiencyChildbusiness.industryGastroenterologymedicine.diseaseFamotidineCrossover studySteatorrheaFamotidineCeliac DiseaseEndocrinologyPancreatinExocrine Pancreatic InsufficiencyFemalemedicine.symptombusinessmedicine.drugDigestive diseases and sciences
researchProduct

Pancreatic insufficiency in celiac disease is not dependent on nutritional status

1994

To determine the relationship between pancreatic secretory capacity and nutritional status in celiac patients, we studied 52 patients with celiac disease (24 males, 28 females; age range 6-36 months) and 30 healthy control subjects (14 males, 16 females; age range 6-42 months). A secretin-cerulein test was performed on all patients, and levels of serum albumin and plasma fibronectin were assayed. In addition, weight/height ratios were calculated in the celiacs, who were then divided into three groups on this basis, as follows: celiacs with weight/height ratioor = 3rd percentile; those with weight/height ratio between the 4th and 10th percentiles; and those with weight/height ratio10th perce…

Malemedicine.medical_specialtyPercentilePhysiologyBiopsySerum albuminNutritional StatusDiseaseStatistics NonparametricPathogenesisSecretinInternal medicineIntestine SmallmedicineHumansProspective StudiesLipaseChi-Square DistributionbiologyChemistryGastroenterologyAlbuminInfantNutritional statusHepatologyCeliac DiseasePancreatic Function TestsEndocrinologyChild Preschoolbiology.proteinExocrine Pancreatic InsufficiencyFemaleCeruletideDigestive Diseases and Sciences
researchProduct

Imaging features of pancreatic metastases: A comparison with pancreatic ductal adenocarcinoma

2018

Purpose: To compare imaging features of pancreatic metastases (PM) with those of pancreatic ductal adenocarcinomas (PDAC). Methods: CT and MR scans of 24 patients with 54 PM and 30 patients with PDAC were reviewed to evaluate the imaging features, which were compared by using a Chi square test. Results: We found a statistically significant difference between PM and PDAC based on location (P < 0.001), margins (P < 0.001), arterial enhancement (P = 0.004), rim enhancement (P < 0.001), pancreatic duct dilatation (P = 0.01), common bile duct dilatation (P = 0.003), vascular involvement (P = 0.02), parenchymal atrophy (P < 0.001), peripancreatic fluid (P = 0.03). Conclusion: Imaging features mig…

Malemedicine.medical_specialtyRadiology Nuclear Medicine and ImagingPancreatic ductal adenocarcinomaLung Neoplasmsendocrine system diseasesMetastaseComputed tomographyAdenocarcinoma030218 nuclear medicine & medical imaging03 medical and health sciences0302 clinical medicinemedicineHumansAbdominal radiology; Adenocarcinoma; Computed tomography; Magnetic resonance; Metastases; Pancreas; Radiology Nuclear Medicine and ImagingPancreaPancreatic carcinomaCarcinoma Renal CellComputed tomographyAgedRetrospective StudiesAged 80 and overmedicine.diagnostic_testbusiness.industrySignificant differenceMagnetic resonance imagingNeoplasms Second PrimaryMiddle Agedmedicine.diseaseMagnetic Resonance ImagingAbdominal radiologydigestive system diseasesKidney NeoplasmsPancreatic Neoplasmsmedicine.anatomical_structureMagnetic resonance030220 oncology & carcinogenesisAdenocarcinomaFemaleRadiologybusinessPancreasTomography X-Ray ComputedCarcinoma Pancreatic Ductal
researchProduct